Kristen R Hollinger, Anjali Sharma, Carolyn Tallon, Lyndah Lovell, Ajit G Thomas, Xiaolei Zhu, Robyn Wiseman, Ying Wu, Siva P Kambhampati, Kevin Liaw, Rishi Sharma, Camilo Rojas, Rana Rais, Sujatha Kannan, Rangaramanujam M Kannan, Barbara S Slusher
Cognitive impairment is a common aspect of multiple sclerosis (MS) for which there are no treatments. Reduced brain N -acetylaspartylglutamate (NAAG) levels are linked to impaired cognition in various neurological diseases, including MS. NAAG levels are regulated by glutamate carboxypeptidase II (GCPII), which hydrolyzes the neuropeptide to N -acetyl-aspartate and glutamate. GCPII activity is upregulated multifold in microglia following neuroinflammation. Although several GCPII inhibitors, such as 2-PMPA, elevate brain NAAG levels and restore cognitive function in preclinical studies when given at high systemic doses or via direct brain injection, none are clinically available due to poor bioavailability and limited brain penetration...
2022: Nanotheranostics